New Zealand markets closed

BIIB Aug 2022 265.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
As of 10:38AM EDT. Market open.
Full screen
Loading interactive chart…
  • Zacks

    Biogen Inc. (BIIB) Up 1.1% Since Last Earnings Report: Can It Continue?

    Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Motley Fool

    Here's What Could Make This Beaten-Down Stock a Buy

    One could write a book (or two) about everything that's happened to Biogen (NASDAQ: BIIB) in the past three years. The company's controversial approval of Alzheimer's disease (AD) medicine Aduhelm makes for a fascinating story, as does the fallout from this approval and the fact that Aduhelm is nowhere close to living up to its lofty potential on the market. With the issues surrounding Aduhelm and Biogen's loss of exclusivity for multiple sclerosis medicine Tecfidera -- which was one of its top-selling products -- the biotech isn't doing too well.

  • Zacks

    Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down

    Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.